JAK抑制剂治疗斑秃:文献综述。

IF 1 Q4 DERMATOLOGY
Jaiden Townsend, Aleksandar Godic
{"title":"JAK抑制剂治疗斑秃:文献综述。","authors":"Jaiden Townsend, Aleksandar Godic","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Alopecia areata (AA) is chronic autoimmune non-scarring hair loss, which can progress to alopecia totalis or universalis. Conventional treatments, such as corticosteroids and immunotherapies, often offer limited temporary benefits in moderate to severe cases. Recent advances have identified Janus kinase (JAK) inhibitors as a promising therapeutic option, targeting cytokine pathways involved in AA pathogenesis. This review explores the current evidence surrounding JAK inhibitors in the management of AA. Clinical trials and case series have demonstrated notable efficacy in promoting hair regrowth, even in extensive disease. Baricitinib and deuruxolitinib have shown particularly strong results, with significant scalp hair regrowth and acceptable safety profiles. Common adverse effects include acne, elevated lipid levels, and mild laboratory abnormalities, although long-term data remain limited. This review summarizes the mechanisms, efficacy outcomes, and safety data of various JAK inhibitors used in AA and highlights the need for further research to establish optimal dosing, treatment duration, and long-term safety.</p>","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"34 ","pages":"117-120"},"PeriodicalIF":1.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of alopecia areata with JAK inhibitors: a review of the literature.\",\"authors\":\"Jaiden Townsend, Aleksandar Godic\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alopecia areata (AA) is chronic autoimmune non-scarring hair loss, which can progress to alopecia totalis or universalis. Conventional treatments, such as corticosteroids and immunotherapies, often offer limited temporary benefits in moderate to severe cases. Recent advances have identified Janus kinase (JAK) inhibitors as a promising therapeutic option, targeting cytokine pathways involved in AA pathogenesis. This review explores the current evidence surrounding JAK inhibitors in the management of AA. Clinical trials and case series have demonstrated notable efficacy in promoting hair regrowth, even in extensive disease. Baricitinib and deuruxolitinib have shown particularly strong results, with significant scalp hair regrowth and acceptable safety profiles. Common adverse effects include acne, elevated lipid levels, and mild laboratory abnormalities, although long-term data remain limited. This review summarizes the mechanisms, efficacy outcomes, and safety data of various JAK inhibitors used in AA and highlights the need for further research to establish optimal dosing, treatment duration, and long-term safety.</p>\",\"PeriodicalId\":45914,\"journal\":{\"name\":\"Acta Dermatovenerologica Alpina Pannonica et Adriatica\",\"volume\":\"34 \",\"pages\":\"117-120\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Dermatovenerologica Alpina Pannonica et Adriatica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

斑秃(AA)是一种慢性自身免疫性非瘢痕性脱发,可发展为全身性或全身性脱发。常规治疗,如皮质类固醇和免疫疗法,通常在中度至重度病例中提供有限的暂时益处。最近的进展已经确定Janus激酶(JAK)抑制剂是一种有希望的治疗选择,靶向参与AA发病机制的细胞因子途径。本文综述了目前有关JAK抑制剂在AA治疗中的作用。临床试验和病例系列证明了促进头发再生的显着功效,甚至在广泛的疾病。Baricitinib和deuruxolitinib显示出特别强的效果,显著的头皮头发再生和可接受的安全性。常见的不良反应包括痤疮、血脂水平升高和轻微的实验室异常,尽管长期数据仍然有限。本文综述了用于AA的各种JAK抑制剂的机制、疗效结果和安全性数据,并强调需要进一步研究以确定最佳剂量、治疗持续时间和长期安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of alopecia areata with JAK inhibitors: a review of the literature.

Alopecia areata (AA) is chronic autoimmune non-scarring hair loss, which can progress to alopecia totalis or universalis. Conventional treatments, such as corticosteroids and immunotherapies, often offer limited temporary benefits in moderate to severe cases. Recent advances have identified Janus kinase (JAK) inhibitors as a promising therapeutic option, targeting cytokine pathways involved in AA pathogenesis. This review explores the current evidence surrounding JAK inhibitors in the management of AA. Clinical trials and case series have demonstrated notable efficacy in promoting hair regrowth, even in extensive disease. Baricitinib and deuruxolitinib have shown particularly strong results, with significant scalp hair regrowth and acceptable safety profiles. Common adverse effects include acne, elevated lipid levels, and mild laboratory abnormalities, although long-term data remain limited. This review summarizes the mechanisms, efficacy outcomes, and safety data of various JAK inhibitors used in AA and highlights the need for further research to establish optimal dosing, treatment duration, and long-term safety.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
8.30%
发文量
38
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信